-
Je něco špatně v tomto záznamu ?
Response of HIV positive patients to the long-term salvage therapy by lopinavir/ritonavir
Václavíková J., Machala L., Stanková M., Linka M., Brůčková M., Vandasová J., Konvalinka J.
Jazyk angličtina Země Nizozemsko
Grantová podpora
NR7843
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Část
Zdroj
- MeSH
- časové faktory MeSH
- dospělí MeSH
- finanční podpora výzkumu jako téma MeSH
- HIV séropozitivita farmakoterapie MeSH
- HIV-1 fyziologie účinky léků MeSH
- inhibitory HIV-proteasy terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- počet CD4 lymfocytů MeSH
- pyrimidinony terapeutické užití MeSH
- ritonavir terapeutické užití MeSH
- RNA virová krev MeSH
- výsledek terapie MeSH
- záchranná terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
BACKGROUND: The cohort of 19 patients on LPV/r salvage regimen was followed for the period of up to 37.5 months. Patient's virologic response was evaluated with regard to the various baseline characteristics. RESULTS: A 73.7% of patients (14 out of 19) achieved viral suppression during the first three months of treatment, either complete (47.4%) or partial (26.3%). This effect was only transient in five cases (virologic rebound emerged after 9 months of treatment on average) and in nine cases the treatment was successful in the long-term analysis (HIV RNA plasma level still undetectable at 31st month of the therapy on average with maximum of 36 months). We analyzed the link between the virologic response and possible predictive factors of treatment efficiency, such as lopinavir mutation score, various individual mutations, previous PI exposure, etc. We also describe changes in the PR sequence associated with poor response to the salvage therapy to LPV/r. CONCLUSIONS:The results of LPV/r salvage therapy were encouraging. About 47% of patients from our study achieved stable suppression of viral replication for 31 months on average. LPV/r proved to be potent inhibitor despite unfavourable prognosis.
- 000
- 03512naa 2200505 a 4500
- 001
- bmc07500987
- 003
- CZ-PrNML
- 005
- 20140730095208.0
- 008
- 071003s2005 ne e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Václavíková, Jana $7 xx0118806
- 245 10
- $a Response of HIV positive patients to the long-term salvage therapy by lopinavir/ritonavir / $c Václavíková J., Machala L., Stanková M., Linka M., Brůčková M., Vandasová J., Konvalinka J.
- 314 __
- $a Institute of Organic Chemistry and Biochemistry, Academy of Science of the Czech Republic, Flemingovo n.2, 166 10 Praha 6, Czech Republic
- 520 9_
- $a BACKGROUND: The cohort of 19 patients on LPV/r salvage regimen was followed for the period of up to 37.5 months. Patient's virologic response was evaluated with regard to the various baseline characteristics. RESULTS: A 73.7% of patients (14 out of 19) achieved viral suppression during the first three months of treatment, either complete (47.4%) or partial (26.3%). This effect was only transient in five cases (virologic rebound emerged after 9 months of treatment on average) and in nine cases the treatment was successful in the long-term analysis (HIV RNA plasma level still undetectable at 31st month of the therapy on average with maximum of 36 months). We analyzed the link between the virologic response and possible predictive factors of treatment efficiency, such as lopinavir mutation score, various individual mutations, previous PI exposure, etc. We also describe changes in the PR sequence associated with poor response to the salvage therapy to LPV/r. CONCLUSIONS:The results of LPV/r salvage therapy were encouraging. About 47% of patients from our study achieved stable suppression of viral replication for 31 months on average. LPV/r proved to be potent inhibitor despite unfavourable prognosis.
- 650 _2
- $a inhibitory HIV-proteasy $x terapeutické užití $7 D017320
- 650 _2
- $a HIV séropozitivita $x farmakoterapie $7 D006679
- 650 _2
- $a pyrimidinony $x terapeutické užití $7 D011744
- 650 _2
- $a ritonavir $x terapeutické užití $7 D019438
- 650 _2
- $a záchranná terapie $7 D016879
- 650 _2
- $a počet CD4 lymfocytů $7 D018791
- 650 _2
- $a HIV-1 $x fyziologie $x účinky léků $7 D015497
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a RNA virová $x krev $7 D012367
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a finanční podpora výzkumu jako téma $7 D012109
- 700 1_
- $a Machala, Ladislav, $d 1954- $7 xx0011470
- 700 1_
- $a Staňková, Marie, $d 1941- $7 jn20000710589
- 700 1_
- $a Linka, M.
- 700 1_
- $a Brůčková, Marie, $d 1930- $7 jo20010093969
- 700 1_
- $a Vandasová, J.
- 700 1_
- $a Konvalinka, Jan, $d 1963- $7 mzk2004208597
- 773 0_
- $w MED00005010 $t Journal of clinical virology $g Roč. 33, č. 4 (2005), s. 319-323 $x 1386-6532
- 910 __
- $a ABA008 $b x $y 1 $z 0
- 990 __
- $a 20071003091744 $b ABA008
- 991 __
- $a 20140730095526 $b ABA008
- 999 __
- $a ok $b bmc $g 616597 $s 469029
- BAS __
- $a 3
- BMC __
- $a 2005 $b 33 $c 4 $d 319-323 $i 1386-6532 $m Journal of clinical virology $x MED00005010
- GRA __
- $a NR7843 $p MZ0
- LZP __
- $a 2007-2/jtjt